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twice daily) from 4 months through 2 years following SCT for the
prevention of zoster. VACV is readily converted to acyclovir in
vivo following oral administration, has potent activity against VZV,
and can be dosed twice daily. Fifty-three VZV-seropositive trans-
plant recipients (17 autologous, 36 allogeneic SCT) were random-
ized at a median of 163 days following SCT. Using an intent-to-
treat analysis, the rate of VZV in the VACV arm was 3 of 27 versus
6 of 26 in the placebo arm (P  .21). All three cases in the VACV
arm occurred after randomization but prior to starting VACV.
Using a modiﬁed intent-to-treat analysis comprised of those sub-
jects randomized who took any study drug, 49 subjects started the
planned therapy with VACV or placebo (4 subjects never started: 2
developed zoster and 2 dropped blood counts prior to the time they
were supposed to start; a ﬁfth subject started drug following res-
olution of zoster starting after randomization). The rate of zoster
was 6 of 26 in the placebo arm versus 0 of 23 in the VACV arm
(P  .03). Thirty subjects completed the planned therapy through
the second year after transplant or ﬁrst episode of zoster. Reasons
for discontinuation in the placebo group included adverse reactions
(nausea/vomiting/dehydration in 2 subjects; elevated transami-
nases, low platelets, and joint pains in 1 subject each) and relapse
(4). Reasons in the VACV group included withdrawal of consent
(4), relapse (3), and adverse reactions (1 leukopenia, 1 cramping
abdominal pain). The 6 episodes of zoster were recorded at a
median of 122 days after randomization (278 days after BMT) and
were complicated by 3 episodes of post-herpetic neuralgia. Vala-
cyclovir at a dose of 1000 mg twice daily through the second year
after transplant is well tolerated and effective in preventing the
outbreak of shingles after SCT.
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Background: Zygomycosis is an emerging opportunistic mycosis
for which few therapies exist and can occur in hematopoietic stem
cell transplant (HSCT) recipients and patients with hematologic
malignancies. We evaluated the use of posaconazole (POS) as
salvage therapy in patients with zygomycosis enrolled in a Scher-
ing-Plough compassionate-use program. Methods: A retrospec-
tive analysis was conducted using questionnaires completed by
investigators treating patients with zygomycosis. Patients were
required to have proven or probable zygomycosis (EORTC/MSG
criteria) and have disease refractory (R) to and/or be intolerant (I)
of prior antifungal therapy. Outcome at 12 weeks was assessed.
Results: The majority (69/91) of patients had proven infection,
and most (48/91) were R or R  I (33/91) to prior therapy. Most
(85%) failed lipid amphotericin B (LAB) therapy, and about half
had 1 month of prior antifungal therapy. Overall success (com-
plete response [CR]  partial response [PR]) was 60% (14% CR,
46% PR). Another 21% of patients had stable disease (SD). Success
by predisposing risk factor (subjects could have had more than 1
risk factor) occurred in 28/48 (60%) patients with hematologic
malignancy, 14/27 (52%) HSCT recipients, and 18/30 (60%) pa-
tients with GVHD. Duration of POS therapy (800 mg/day oral
suspension) ranged from 6 days to nearly 3 years. Success was also
generally similar by site of infection: 23/42 (54%) sinus, 24/37
(65%) pulmonary, 8/13 (62%) cutaneous, 8/11 (73%) brain, and
5/11 (46%) orbital infections. Success was observed for various
species of Zygomycetes. Combination therapy (POS  LAB) for
	10 days in 15 heavily immunosuppressed patients resulted in
similar response (7% CR, 47% PR, 27% SD). Sixty-four patients
(70%) had adjunct surgical debridement (38 patients before POS,
9 patients during POS, 17 patients both before and during POS);
26 patients had no surgery. Thirty-ﬁve patients died while on POS
or within 1 month of follow-up, though only 15 deaths were
considered related to zygomycosis.
Conclusions: Overall success with POS was high, including
patients with hematologic malignancies and HSCT recipients. The
favorable survival rate in this case series provides encouraging data
regarding POS as an alternative to LAB. Further well-controlled
clinical studies are warranted.
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The Bone Marrow Transplant Unit at Cincinnati Children’s
Hospital Medical Center (CCHMC) is an 18 bed unit that serves
children from all over the country and internationally for trans-
plants. The usual range of stay in the hospital is about 30–60 days,
but can be much longer. We have found the patients and families
bring not only their medical needs, but many social issues must be
understood and addressed. These include issues related to being
away from home, loss of normal resources, ﬁnancial stress, family
conﬂicts, health and/or behavioral problems of family members,
transportation problems, insurance difﬁculties, and the list contin-
ues. The community of patients and families forms somewhat of a
village. The instant village of the BMT unit requires much atten-
tion and support from a vast array of staff in addition to the medical
team. The needs of the patient and families are as varied and
complicated as are the diseases which brought them to our hospi-
tal. An interdisciplinary and family-centered approach called the
Family Support Network (FSN) has been developed in the Divi-
sion of Hematology and Oncology at CCHMC to address the
needs of the patients and families. The social worker, school
intervention specialist, child life specialist, massage therapist, chap-
lain, and ﬁnancial counselor have become essential personnel to
the transplant process. Every member of the FSN uses a support-
ive, family-centered, and solution-focused approach which be-
comes the new culture for the families. Families are offered support
groups, individual counseling, educational opportunities, and var-
ious self-care interventions (massages, family meals, make-overs,
movies). The patients and families, in turn, utilize services and
begin to support themselves and each other in more adaptive ways.
The acclimation process for patients and families into the culture
begins before they ever come to the hospital, through telephone
contacts and written materials. This process continues in person
during treatment and after-care phases. The FSN staff also pro-
vides support for the nursing and medical team to reduce stress
caused by working with high-acuity patients through de-brieﬁng
sessions, massages, supportive counseling, and educational inter-
ventions (Table 1).
Table 1. Services of the Family Support Network (FSN)
Social Work
School
Intervention Child Life Pastoral Care Financial Service
Emotional
support and
crisis
counseling
Facilitate home
instruction
Creative and
innovative
medical
play
Liaison with
community
clergy
Customer service
for financial
issues
Family support
and diagnosis
onward
Individualized
Education Plans
Sibling
support
Spiritual and
emotional
support
Pre-
authorizations
Resource
connections/
advocacy
School
reintegration
Support and
distraction
Visitation and
prayer
Pre-certifications
Teaching,
education, and
consulting
Pre-school
through college
Therapeutic
play
Reflection Verification of
financial
eligibility
The FSN is committed to helping patients and families through
BMT process.
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